489 related articles for article (PubMed ID: 16767301)
1. [Treatment of dyslipidemia: how and when to combine lipid lowering drugs].
Schulz I
Arq Bras Endocrinol Metabol; 2006 Apr; 50(2):344-59. PubMed ID: 16767301
[TBL] [Abstract][Full Text] [Related]
2. Optimal management of combined dyslipidemia: what have we behind statins monotherapy?
Tenenbaum A; Fisman EZ; Motro M; Adler Y
Adv Cardiol; 2008; 45():127-153. PubMed ID: 18230960
[TBL] [Abstract][Full Text] [Related]
3. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
Cziraky MJ; Watson KE; Talbert RL
J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
[TBL] [Abstract][Full Text] [Related]
4. [HDL, or non-HDL: that is the question. Possibilities of pharmacological treatment in residual dyslipidaemia].
Bajnok L
Orv Hetil; 2014 Jan; 155(2):62-8. PubMed ID: 24389322
[TBL] [Abstract][Full Text] [Related]
5. Combination therapy for combined dyslipidemia.
Xydakis AM; Ballantyne CM
Am J Cardiol; 2002 Nov; 90(10B):21K-29K. PubMed ID: 12467937
[TBL] [Abstract][Full Text] [Related]
6. Long-term safety and efficacy of a combination of niacin extended release and simvastatin in patients with dyslipidemia: the OCEANS study.
Karas RH; Kashyap ML; Knopp RH; Keller LH; Bajorunas DR; Davidson MH
Am J Cardiovasc Drugs; 2008; 8(2):69-81. PubMed ID: 18422390
[TBL] [Abstract][Full Text] [Related]
7. Use of combination therapy for dyslipidemia: a lipid clinic approach.
Brown AS
Am J Cardiol; 2002 Nov; 90(10B):44K-49K. PubMed ID: 12467939
[TBL] [Abstract][Full Text] [Related]
8. Niacin-ER/statin combination for the treatment of dyslipidemia: focus on low high-density lipoprotein cholesterol.
Chrysant SG; Ibrahim M
J Clin Hypertens (Greenwich); 2006 Jul; 8(7):493-9; quiz 500-1. PubMed ID: 16849903
[TBL] [Abstract][Full Text] [Related]
9. Changes in lipoprotein particle number with ezetimibe/simvastatin coadministered with extended-release niacin in hyperlipidemic patients.
Le NA; Jin R; Tomassini JE; Tershakovec AM; Neff DR; Wilson PW
J Am Heart Assoc; 2013 Aug; 2(4):e000037. PubMed ID: 23926117
[TBL] [Abstract][Full Text] [Related]
10. Management of dyslipidemia in women in the post-hormone therapy era.
Mosca L
J Gen Intern Med; 2005 Mar; 20(3):297-305. PubMed ID: 15836536
[TBL] [Abstract][Full Text] [Related]
11. Lowering low-density lipoprotein cholesterol: statins, ezetimibe, bile acid sequestrants, and combinations: comparative efficacy and safety.
Hou R; Goldberg AC
Endocrinol Metab Clin North Am; 2009 Mar; 38(1):79-97. PubMed ID: 19217513
[TBL] [Abstract][Full Text] [Related]
12. Prolonged-release nicotinic acid for the management of dyslipidemia: an update including results from the NAUTILUS study.
Vogt A; Kassner U; Hostalek U; Steinhagen-Thiessen E
Vasc Health Risk Manag; 2007; 3(4):467-79. PubMed ID: 17969377
[TBL] [Abstract][Full Text] [Related]
13. Extended-release niacin or ezetimibe and carotid intima-media thickness.
Taylor AJ; Villines TC; Stanek EJ; Devine PJ; Griffen L; Miller M; Weissman NJ; Turco M
N Engl J Med; 2009 Nov; 361(22):2113-22. PubMed ID: 19915217
[TBL] [Abstract][Full Text] [Related]
14. Diabetic dyslipidemia: a practical guide to therapy.
Tovar JM; Bazaldua OV; Loffredo A
J Fam Pract; 2008 Jun; 57(6):377-88. PubMed ID: 18544321
[TBL] [Abstract][Full Text] [Related]
15. 'Trig-onometry': non-high-density lipoprotein cholesterol as a therapeutic target in dyslipidaemia.
Jacobson TA
Int J Clin Pract; 2011 Jan; 65(1):82-101. PubMed ID: 21105969
[TBL] [Abstract][Full Text] [Related]
16. Nonstatin therapies for management of dyslipidemia: a review.
Sando KR; Knight M
Clin Ther; 2015 Oct; 37(10):2153-79. PubMed ID: 26412799
[TBL] [Abstract][Full Text] [Related]
17. Statins, fibrates, nicotinic acid, cholesterol absorption inhibitors, anion-exchange resins, omega-3 fatty acids: which drugs for which patients?
Drexel H
Fundam Clin Pharmacol; 2009 Dec; 23(6):687-92. PubMed ID: 19682084
[TBL] [Abstract][Full Text] [Related]
18. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
Nesto RW
Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
[TBL] [Abstract][Full Text] [Related]
19. Combination therapy for dyslipidemia: safety and regulatory considerations.
Davidson MH
Am J Cardiol; 2002 Nov; 90(10B):50K-60K. PubMed ID: 12467940
[TBL] [Abstract][Full Text] [Related]
20. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update.
Reiner Z
Nutr Metab Cardiovasc Dis; 2013 Sep; 23(9):799-807. PubMed ID: 23932901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
